drugset / Trial / NCT01027169
A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The primary purpose of this study is to investigate the pharmacokinetics (behavior of the compound in the body) of safinamide in patients with different degrees of hepatic (liver) impairment in comparison to matched subjects with normal hepatic function.
Timeline
- Start
- 2009-04
- Primary completion
- 2009-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Safinamide | Small molecule | 50 mg | — |
Indications
No indication recorded.